<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Conference on Retroviruses and Opportunistic Infections</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Atea Pharma presents data on compounds for hepatitis E</title>
      <description>
        <![CDATA[Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729514</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729514-atea-pharma-presents-data-on-compounds-for-hepatitis-e</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Liver-infection-hepatitis-e-virus.webp?t=1773155425" type="image/jpeg" medium="image" fileSize="758663">
        <media:title type="plain">Illustration of liver infected by hepatitis E</media:title>
      </media:content>
    </item>
    <item>
      <title>KLF16 as potential target for HIV management</title>
      <description>
        <![CDATA[HIV-1 persistence in latent reservoirs of T lymphoid and myeloid origin is a major barrier for the cure of the disease, with complex and multifactorial mechanisms behind HIV-1 latency; thus, investigating these mechanisms is key for future targeted HIV therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729376</guid>
      <pubDate>Thu, 05 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729376-klf16-as-potential-target-for-hiv-management</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NHI-NIAID-HIV-1-virus-particles-pink.webp?t=1752677386" type="image/jpeg" medium="image" fileSize="1133167">
        <media:title type="plain">Transmission electron micrograph of HIV-1 virus particles</media:title>
        <media:description type="plain">HIV-1 virus particles. Credit: NIAID, CC BY 2.0</media:description>
      </media:content>
    </item>
    <item>
      <title>Preclinical data support continued testing of Gilead’s HIV candidate GS-3242</title>
      <description>
        <![CDATA[Gilead Sciences Inc.’s integrase strand transfer inhibitor (INSTI) GS-3242 is in early clinical development for HIV infection (NCT07001319). The company presented nonclinical data on the candidate at the recent CROI meeting in Denver.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729373</guid>
      <pubDate>Thu, 05 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729373-preclinical-data-support-continued-testing-of-gileads-hiv-candidate-gs-3242</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>Anticancer drug exerts potent HIV antiviral effects</title>
      <description>
        <![CDATA[A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported. Because cancer cells and HIV-infected cells have similar features, researchers from City of Hope National Medical Center tested the anit-HIV effects of a small-molecule compound, AOH-1996, that targets caPCNA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729327</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729327-anticancer-drug-exerts-potent-hiv-antiviral-effects</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/HIV-AIDS-viral-structure.webp?t=1707321297" type="image/jpeg" medium="image" fileSize="238698">
        <media:title type="plain">Cross section illustration of HIV virus parts</media:title>
      </media:content>
    </item>
    <item>
      <title>BNT-351, long-acting bNAb with potent HIV neutralization</title>
      <description>
        <![CDATA[Broadly neutralizing antibodies (bNAbs) target conserved HIV envelope regions to neutralize diverse strains, eliminate infected cells and reduce viral reservoirs, complementing antiretroviral therapy and supporting prevention and functional cure strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729134</guid>
      <pubDate>Mon, 02 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729134-bnt-351-long-acting-bnab-with-potent-hiv-neutralization</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/3D-HIV.webp?t=1709829200" type="image/jpeg" medium="image" fileSize="273128">
        <media:title type="plain">Illustration of HIV particles</media:title>
      </media:content>
    </item>
    <item>
      <title>CROI 2026: Science and funding cuts reverse decades of progress against HIV</title>
      <description>
        <![CDATA[The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension of thousands of NIH research projects led to an immediate collapse of essential services, from HIV prevention to access to treatment. At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, scientists, activists, and health professionals presented data illustrating the scale of the damage and warned of a historic setback in the global HIV response.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729112</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729112-croi-2026-science-and-funding-cuts-reverse-decades-of-progress-against-hiv</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/HIV-with-graphs-numbers-and-map.webp?t=1772205424" type="image/jpeg" medium="image" fileSize="1068230">
        <media:title type="plain">HIV with graphs, numbers and map</media:title>
      </media:content>
    </item>
    <item>
      <title>CROI 2026 highlights depression and cognitive vulnerability in HIV</title>
      <description>
        <![CDATA[The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral therapy. At the Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, the scientific community examined how the virus affects the brain, how the reservoir is established in the CNS, and which genetic, immunological or treatment-related factors influence cognitive health.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729051</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729051-croi-2026-highlights-depression-and-cognitive-vulnerability-in-hiv</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Depression-concept-with-human-broken-brain-and-heavy-rain.webp?t=1772119734" type="image/jpeg" medium="image" fileSize="692951">
        <media:title type="plain">Depression concept with human, broken brain and heavy rain</media:title>
      </media:content>
    </item>
    <item>
      <title>MDL-001: oral polymerase inhibitor with dual HBV/HCV activity </title>
      <description>
        <![CDATA[Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the viral polymerase.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729032</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729032-mdl-001-oral-polymerase-inhibitor-with-dual-hbv-hcv-activity</link>
    </item>
    <item>
      <title>CROI 2026: Neurodegeneration, the challenge of aging with HIV  </title>
      <description>
        <![CDATA[Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many of them are aging in good health. However, others present symptoms of cognitive decline. HIV can reach the brain and establish a reservoir there. Yet, it is still unknown what this reservoir is like, which cells are affected, and which comorbidities are typical of aging or are associated with the virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729031</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729031-croi-2026-neurodegeneration-the-challenge-of-aging-with-hiv</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Brain-and-virus-with-chromosome.webp?t=1772031510" type="image/jpeg" medium="image" fileSize="1307640">
        <media:title type="plain">Brain and virus with chromosome</media:title>
      </media:content>
    </item>
    <item>
      <title>Long COVID science is progressing, though therapies have not yet followed</title>
      <description>
        <![CDATA[In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718435</guid>
      <pubDate>Tue, 18 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718435-long-covid-science-is-progressing-though-therapies-have-not-yet-followed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-with-long-shadow.webp?t=1674598407" type="image/png" medium="image" fileSize="78917">
        <media:title type="plain">Red coronavirus with long shadow</media:title>
      </media:content>
    </item>
    <item>
      <title>ALG-097558 confirmed as an effective pan-coronavirus strategy</title>
      <description>
        <![CDATA[Although safe and effective vaccines for SARS-CoV-2 have been successfully developed, there are currently no therapeutic approaches available for treating acute infection, particularly for individuals at high risk of severe disease progression, and for preparedness against a potential new coronavirus pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718315</guid>
      <pubDate>Mon, 17 Mar 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718315-alg-097558-confirmed-as-an-effective-pan-coronavirus-strategy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-variants.webp?t=1611174655" type="image/png" medium="image" fileSize="503715">
        <media:title type="plain">Coronavirus variants</media:title>
      </media:content>
    </item>
    <item>
      <title>In HIV, draining the reservoir means understanding the brain</title>
      <description>
        <![CDATA[The availability of effective antiretroviral therapy has lowered the risk, and the severity, of neural sequelae of HIV infection. “Early in the HIV pandemic, approximately 15% of people with HIV had dementia and or encephalitis,” Howard Fox told his audience. “Fortunately, with treatment, the prevalence of these severe disorders has been greatly lowered. But there is persistence of what are called more minor disorders – which are not minor if you have them.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/718291</guid>
      <pubDate>Fri, 14 Mar 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718291-in-hiv-draining-the-reservoir-means-understanding-the-brain</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Neurology-brain-magnifying-glass.webp?t=1741964843" type="image/jpeg" medium="image" fileSize="91475">
        <media:title type="plain">Illustration of magnifying glass inspecting brain</media:title>
      </media:content>
    </item>
    <item>
      <title>Long COVID science is progressing, though therapies have not yet followed</title>
      <description>
        <![CDATA[In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718345</guid>
      <pubDate>Fri, 14 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718345-long-covid-science-is-progressing-though-therapies-have-not-yet-followed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-with-long-shadow.webp?t=1674598407" type="image/png" medium="image" fileSize="78917">
        <media:title type="plain">Red coronavirus with long shadow</media:title>
      </media:content>
    </item>
    <item>
      <title>SP-38 potently inhibits HIV-1 replication by inducing defective particle morphology</title>
      <description>
        <![CDATA[It was previously demonstrated that the HIV-1 integrase (IN)-interacting host factor INI1/SMARCB1 binds to HIV-1 IN through its Rpt1 domain of INI1 (INI1-Rpt1) and plays a key role in assembly and particle production.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718220</guid>
      <pubDate>Thu, 13 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718220-sp-38-potently-inhibits-hiv-1-replication-by-inducing-defective-particle-morphology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-HIV-1-virus-particles.webp?t=1719502120" type="image/jpeg" medium="image" fileSize="549861">
        <media:title type="plain">Transmission electron micrograph of HIV-1 virus particles </media:title>
        <media:description type="plain">Transmission electron micrograph of HIV-1 virus particles (red/yellow) budding and replicating from a segment of a chronically infected H9 cell (blue/teal). Credit: NIAID, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>Long COVID science is progressing, though therapies have not yet followed</title>
      <description>
        <![CDATA[In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718217</guid>
      <pubDate>Thu, 13 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718217-long-covid-science-is-progressing-though-therapies-have-not-yet-followed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-with-long-shadow.webp?t=1674598407" type="image/png" medium="image" fileSize="78917">
        <media:title type="plain">Red coronavirus with long shadow</media:title>
      </media:content>
    </item>
    <item>
      <title>At CROI, HIV cure trials raise hopes for broader applicability</title>
      <description>
        <![CDATA[At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the first HIV cure trial conducted in Africa, the RIO trial and others showed that perhaps, a broadly useful cure is on the horizon.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718191</guid>
      <pubDate>Tue, 11 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718191-at-croi-hiv-cure-trials-raise-hopes-for-broader-applicability</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>At CROI, HIV cure trials raise hopes for broader applicability</title>
      <description>
        <![CDATA[At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the first HIV cure trial conducted in Africa, the RIO trial and others showed that perhaps, a broadly useful cure is on the horizon.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718133</guid>
      <pubDate>Tue, 11 Mar 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718133-at-croi-hiv-cure-trials-raise-hopes-for-broader-applicability</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>VH-937 demonstrates robust antiviral activity against HIV-1 strains resistant to prior maturation inhibitors</title>
      <description>
        <![CDATA[Researchers from Viiv Healthcare Ltd. presented preclinical data for the next-generation maturation inhibitor (MI) VH-3739937 (VH-937, zegruvirimat), currently in clinical testing for the treatment of HIV.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706762</guid>
      <pubDate>Thu, 21 Mar 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706762-vh-937-demonstrates-robust-antiviral-activity-against-hiv-1-strains-resistant-to-prior-maturation-inhibitors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/CROI-resized.webp?t=1676909780" type="image/png" medium="image" fileSize="1846657">
        <media:title type="plain">HIV-1 virus particle</media:title>
        <media:description type="plain">HIV-1 virus particle. Credit: National Institute of Allergy and Infectious Diseases.</media:description>
      </media:content>
    </item>
    <item>
      <title>GSK-445A reduces HIV viral load from cells of people with HIV infection</title>
      <description>
        <![CDATA[The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706632</guid>
      <pubDate>Mon, 18 Mar 2024 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706632-gsk-445a-reduces-hiv-viral-load-from-cells-of-people-with-hiv-infection</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Infectious-HIV-3D-model-NIH.webp?t=1745260069" type="image/jpeg" medium="image" fileSize="310210">
        <media:title type="plain">HIV 3D model</media:title>
        <media:description type="plain">3D-printed model of HIV that has been cut in half to expose 
the interior of the virion. Credit: NIAID, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>AM-80 enhances NK cytotoxicity against HIV-infected CD4+ T cells</title>
      <description>
        <![CDATA[Retinoids are derivatives of vitamin A that target the retinoid receptors and induce antiproliferative effects and cell death. George Washington University has tested a series of different retinoids, including alitretinoin, tazarotene and AM-80, also known as tamibarotene, for their efficacy against HIV-infected CD4+ T cells regarding their ability to enhance the cytotoxic effect of NK cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706597</guid>
      <pubDate>Fri, 15 Mar 2024 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706597-am-80-enhances-nk-cytotoxicity-against-hiv-infected-cd4-t-cells</link>
    </item>
    <item>
      <title>CROI 2024: New options, and concerns, on HIV drug resistance</title>
      <description>
        <![CDATA[One topic at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver this month was that resistance to antiretroviral therapy (ART) has become a public health problem for people living with HIV. Without a vaccine or a cure, these patients depend on treatments that suppress viremia by preventing the virus from replicating. They are lifelong treatments and, until new advances succeed in eradicating the virus from reservoirs, the only option available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706559</guid>
      <pubDate>Tue, 12 Mar 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706559-croi-2024-new-options-and-concerns-on-hiv-drug-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/AdobeStock_411836983.webp?t=1745260197" type="image/jpeg" medium="image" fileSize="427124">
        <media:title type="plain">HIV virus cells</media:title>
      </media:content>
    </item>
    <item>
      <title>The ‘data desert’ of pediatric HIV</title>
      <description>
        <![CDATA[Several presentations at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held in Denver from March 3 to 6, 2024, focused on childhood HIV and highlighted the lack of pediatric data. The epicenter of this pandemic in the youngest is in the southern region of the African continent. However, there are few studies for children with HIV, mostly for the northern hemisphere.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706404</guid>
      <pubDate>Mon, 11 Mar 2024 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706404-the-data-desert-of-pediatric-hiv</link>
    </item>
    <item>
      <title>At CROI 2024, challenges and roads to new HIV vaccines</title>
      <description>
        <![CDATA[Overall, the story of HIV is one of astounding success. But to declare victory, it will be necessary to develop a vaccine. The opening session of the 31st Conference on Retroviruses and Opportunistic Infections (CROI) 2024 looked back to the failures but also the advances in research, all the steps that over the years brought the basic science knowledge that could bring an HIV vaccine in the future. This year, the former director of the Viral Pathogenesis Laboratory at the NIAID Vaccine Research Center, Barney Graham, was named for the Bernard Field Lecture, where he presented “Modern vaccinology: a legacy of HIV research.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/706366</guid>
      <pubDate>Thu, 07 Mar 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706366-at-croi-2024-challenges-and-roads-to-new-hiv-vaccines</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/3D-HIV.webp?t=1709829200" type="image/jpeg" medium="image" fileSize="273128">
        <media:title type="plain">Illustration of HIV particles</media:title>
      </media:content>
    </item>
    <item>
      <title>CROI 2024: HIV is active in the CNS despite ART</title>
      <description>
        <![CDATA[On March 4, 2024, several groups of scientists discussed the challenges of investigating the effects of HIV in the central nervous system (CNS) at the oral abstract session on neuropathogenesis of HIV held during the 31st Conference on Retroviruses and Opportunistic Infections (CROI), in Denver. A cure for HIV will require eliminating the virus in all its reservoirs, those tissues where HIV remains latent but retains the capacity for reactivation and replication. However, despite antiretroviral therapy (ART), the virus could continue to replicate continuously at a low level in some reservoirs, including the CNS.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706267</guid>
      <pubDate>Tue, 05 Mar 2024 09:05:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706267-croi-2024-hiv-is-active-in-the-cns-despite-art</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Virus-nerve-CNS.webp?t=1709653711" type="image/jpeg" medium="image" fileSize="410297">
        <media:title type="plain">Virus particles attacking neuron</media:title>
      </media:content>
    </item>
    <item>
      <title>CROI 2024: HIV is active in the CNS despite ART</title>
      <description>
        <![CDATA[On March 4, 2024, several groups of scientists discussed the challenges of investigating the effects of HIV in the central nervous system (CNS) at the oral abstract session on neuropathogenesis of HIV held during the 31st Conference on Retroviruses and Opportunistic Infections (CROI), in Denver. A cure for HIV will require eliminating the virus in all its reservoirs, those tissues where HIV remains latent but retains the capacity for reactivation and replication. However, despite antiretroviral therapy (ART), the virus could continue to replicate continuously at a low level in some reservoirs, including the CNS.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706309</guid>
      <pubDate>Tue, 05 Mar 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706309-croi-2024-hiv-is-active-in-the-cns-despite-art</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Virus-nerve-CNS.webp?t=1709653711" type="image/jpeg" medium="image" fileSize="410297">
        <media:title type="plain">Virus particles attacking neuron</media:title>
      </media:content>
    </item>
    <item>
      <title>Düsseldorf patient cured of HIV after stem cell transplant</title>
      <description>
        <![CDATA[Fifteen years ago, at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI), researchers announced that they had cured a patient – Timothy Ray Brown, initially known only as the Berlin Patient to preserve his privacy – of HIV through a hematopoietic stem cell transplant. Now, as researchers are gathered in Seattle for CROI 2023, reports of another cured patient were published Feb. 20, 2023, in <em>Nature Medicine</em>. Ten years after receiving a hematopoietic stem cell transplant, and 4 years after stopping antiretroviral treatment (ART), a 53-year-old patient may have been cured of HIV infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694397</guid>
      <pubDate>Mon, 20 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694397-dusseldorf-patient-cured-of-hiv-after-stem-cell-transplant</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/CROI-resized.webp?t=1676909780" type="image/png" medium="image" fileSize="1846657">
        <media:title type="plain">HIV-1 virus particle</media:title>
        <media:description type="plain">HIV-1 virus particle. Credit: National Institute of Allergy and Infectious Diseases.</media:description>
      </media:content>
    </item>
    <item>
      <title>Neuropathy may unify disparate long COVID symptoms</title>
      <description>
        <![CDATA[Researchers from Massachusetts General Hospital have identified peripheral neuropathy in more than half of a group of long COVID patients, suggesting that it may be a mechanism that contributes to multiple, seemingly disparate, long COVID symptoms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516564</guid>
      <pubDate>Wed, 02 Mar 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516564-neuropathy-may-unify-disparate-long-covid-symptoms</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Viruses-infecting-neurons.webp?t=1636468524" type="image/png" medium="image" fileSize="583497">
        <media:title type="plain">Viruses-infecting-neurons.png</media:title>
      </media:content>
    </item>
    <item>
      <title>CROI 2022: Predicting the future to get ahead of viruses</title>
      <description>
        <![CDATA[Broadly neutralizing antibodies are one of the most powerful weapons against HIV. And like everything that is effective in the fight against HIV, they are hard to come by.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516172</guid>
      <pubDate>Thu, 17 Feb 2022 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516172-croi-2022-predicting-the-future-to-get-ahead-of-viruses</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-T-cell.webp?t=1602003566" type="image/png" medium="image" fileSize="638863">
        <media:title type="plain">HIV-infected T cells</media:title>
        <media:description type="plain">HIV-infected T cells. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>Still no HIV vaccine, but optimism fueled by ‘amazing’ science, ‘astounding’ technology</title>
      <description>
        <![CDATA[Barely more than two years into the COVID-19 pandemic, there are five approved vaccines against SARS-CoV-2 available in the U.S. Forty years into the HIV pandemic, there are none. That contrast was repeatedly made by speakers at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI).]]>
      </description>
      <guid>http://www.bioworld.com/articles/516137</guid>
      <pubDate>Wed, 16 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516137-still-no-hiv-vaccine-but-optimism-fueled-by-amazing-science-astounding-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Global-vaccine.webp?t=1645055390" type="image/png" medium="image" fileSize="489025">
        <media:title type="plain">Global vaccine.png</media:title>
        <media:description type="plain">Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>CROI 2022: HIV remission – with transplant, without GVHD – brings hope and insights</title>
      <description>
        <![CDATA[At the 2022 Conference on Retroviruses and Opportunistic Infections (CROI), investigators reported on a fourth patient who has achieved HIV remission after a stem cell transplant. The patient is the first woman and the first mixed-race person to achieve HIV remission through a transplant procedure. In 2017, she was transplanted with cord blood stem cells lacking a functional CCR5 receptor, which prevents HIV from entering cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516085</guid>
      <pubDate>Tue, 15 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516085-croi-2022-hiv-remission-with-transplant-without-gvhd-brings-hope-and-insights</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
  </channel>
</rss>
